A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B

被引:32
作者
Honorati, MC
Palareti, A
Dolzani, P
Busachi, CA
Rizzoli, R
Facchini, A
机构
[1] Univ Bologna, Lab Immunol & Genet, Ist Ric Codivilla Putti IOR, I-40136 Bologna, Italy
[2] Univ Bologna, Dipartimento Med Interna & Gastroenterol, I-40136 Bologna, Italy
[3] Univ Bologna, Dipartimento Sci Informaz, I-40136 Bologna, Italy
[4] Univ Chieti, Ist Morfol Umana Normale, Chieti, Italy
关键词
hepatitis B vaccination; anti-HBs; recombinant vaccine; plasma-derived vaccine; antibody kinetic;
D O I
10.1046/j.1365-2249.1999.00866.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The determination of serum levels of antibodies against hepatitis B virus surface antigen (anti-HBs) after hepatitis B vaccination is currently the only simple test available to predict the decay of protection and to plan the administration of booster doses. A total of 3085 vaccine recipients of plasma-derived and recombinant vaccine have been followed for 10 years to determine the kinetics of anti-HBs production and to construct a mathematical model which could efficiently predict the anti-HBs level decline. The anti-HBs peak level was reached 68 days after the last dose of recombinant vaccine and 138 days after the last dose of plasma-derived vaccines. The age of vaccinees negatively influenced the anti-HBs levels and also the time necessary to reach the anti-HBs peak. A bilogarithmic mathematical model (log(10) level, log(10) time) of anti-HBs decay has been constructed on a sample of recombinant vaccine recipients and subsequently validated on different samples of recombinant or plasma-derived vaccine recipients. Age, gender, type of vaccine (recombinant or plasma-derived), number of vaccine doses (three or four) did not influence the mathematical model of antibody decay. The program can be downloaded at the site: http://www2.stat.unibo.it/palareti/vaccine.htm. Introducing an anti-HBs determination obtained after the peak, the program calculates a prediction of individual anti-HBs decline and allows planning of an efficient booster policy.
引用
收藏
页码:121 / 126
页数:6
相关论文
共 29 条
[1]  
BENHAMOU E, 1986, NEW ENGL J MED, V314, P1710
[2]   SCHEDULING OF REVACCINATION AGAINST HEPATITIS-B VIRUS [J].
COURSAGET, P ;
YVONNET, B ;
GILKS, WR ;
WANG, CC ;
DAY, NE ;
CHIRON, JP ;
DIOPMAR, I .
LANCET, 1991, 337 (8751) :1180-1183
[3]   12-YEAR FOLLOW-UP-STUDY OF HEPATITIS-B IMMUNIZATION OF SENEGALESE INFANTS [J].
COURSAGET, P ;
LEBOULLEUX, D ;
SOUMARE, M ;
LECANN, P ;
YVONNET, B ;
CHIRON, JP ;
COLLSECK, AM ;
DIOPMAR, I .
JOURNAL OF HEPATOLOGY, 1994, 21 (02) :250-254
[4]   CELLULAR-RESPONSE AND ANTI-HBS SYNTHESIS INVITRO AFTER VACCINATION WITH YEAST-DERIVED RECOMBINANT HEPATITIS VACCINE [J].
DEGRASSI, A ;
MARIANI, E ;
HONORATI, MC ;
RODA, P ;
MINIERO, R ;
CAPELLI, M ;
FACCHINI, A .
VACCINE, 1992, 10 (09) :617-622
[5]  
DING LM, 1993, CLIN INFECT DIS, V17, P475
[6]   HEPATITIS [J].
EDDLESTON, A .
LANCET, 1990, 335 (8698) :1142-1145
[7]  
GERKEN G, 1988, Z GASTROENTEROL, V26, P374
[8]   QUANTIFICATION OF HEPATITIS-B VACCINE-INDUCED ANTIBODIES AS A PREDICTOR OF ANTI-HBS PERSISTENCE [J].
GESEMANN, M ;
SCHEIERMANN, N .
VACCINE, 1995, 13 (05) :443-447
[9]   PROTECTIVE EFFICACY OF A RECOMBINANT DNA VACCINE AGAINST HEPATITIS-B IN MALE-HOMOSEXUALS - RESULTS AT 36 MONTHS [J].
GOILAV, C ;
PRINSEN, H ;
PIOT, P .
VACCINE, 1990, 8 :S50-S52
[10]  
GOODWIN JS, 1995, NUTR REV, V53, pS41